利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Acclaro, Bausch Health, BTL, Cytrellis, Sofwave,

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Bausch, Cytrellis, Sofwave

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Acclaro, Allergan, Bausch Health, BTL, Cytrellis, Galderma, Sofwave,

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: PI for Galderma

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: GALDERMA

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: a. The advent of glucagon-like peptide-1 receptor agonists (GLP1RA) has provided groundbreaking options for obesity and type 2 diabetes management. Despite therapeutic success, subsequent unintended effects such as accelerated facial aging have been noted. ObjectivesThis review aims to delve deeper into the underlying mechanisms and provide insights into the intricate relationship between GLP-1RA, adipose tissue, and premature facial aging, thereby challenging conventional perceptions and highlighting the need for a nuanced understanding of their effects on facial alterations. Methods:A compre

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Show results and therapeutic options in cases of Non-GLP-1 facial lipoatrophy.

Introduction: Plastic surgeon Oscar Ramirez established the "double ogee line" as the curve of beauty in the midface. Different causes lead to the loss of this beauty line because they provoke the loss of fatty tissue in the midface. Different procedures have been described to restore volume in the midface.

Materials / method: Patients with different cases of midface fat loss not caused by GLP-1 facial lipoatrophy were treated by the author with synthetic fillers, fat grafts, and the placement of silicone, polytetrafluoroethylene, and polyethylene malar implants.

Results: The results obtained with the different therapeutic options are shown.

Conclusion: Depending on the degree of medial facial lipoatrophy and its causes, successful permanent or definitive results can be obtained. The use of facial implants is considered ideal in cases where a significant amount of volume is to be recovered permanently.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: We present a series of 31 consecutive patients safely and successfully treated with regenerative hyaluronic acid injections, in order to reverse the soft tissue atrophy caused by prolonged inflammatory filler associated reactions with no recurrency of the latter.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: The objectives are to educate the audience on the different noninvasive energy based device technologies (including newer technology or indications) and soft tissue injectables that the author uses together with facial aesthetic procedures. I will show how to incorporate these with smaller segue procedures in middle age as well as surgical face and necklifting procedures (in the more advanced aging population). Understanding the increased demand for these procedures with the advent of rapid medical weight loss with GLP-1 agonists (like semaglutide) and how to manage this is also discussed.

Introduction: The combination of nonsurgical device technology, cosmetic injectables, and tissue biologics in conjunction with and after facelifting has become an important part of her 100% aesthetic practice. Therefore, a review of current noninvasive technology used such as laser, radiofrequency-assisted liposuction, radiofrequency microneedling, and a newer parallel-beam ultrasound device will be done, along with injectables.

Materials / method: Injectables and noninvasive device technology for aesthetic indications are a huge part of the cosmetic practice, especially that of the plastic surgeon. A major increase in patients seeking medically-supervised weight loss with GLP-1s such as semaglutide in this practice has only added to the number of patients seeking noninvasive lifting and filling, as well as surgical rhytidectomy. Many cases are more complicated with a history of years of previous EBD technology and fillers applied under the skin in this generation of facelift patients seeking treatment.

Results: The presentation will also focus on the usage of advanced HA and non-HA injectable techniques, fat, and tissue biologics (such as exosomes and PRP) to enhance aesthetic results of various procedures such as facelift, necklift, blepharoplasty, browlift, and treatment of malar bags. The efficacy of these techniques when used with minimally invasive procedures such as RFAL , or as standalone treatments in our medical spa will be discussed; safe methods of combination therapy such as SUPERB (parallel beam ultrasound technology) and RF microneedling with or without dermal fillers will be detailed.

Conclusion: Using injectables and nonsurgical technology to improve the aesthetic appearance of concerns such as fine rhytides, pre-existing poor skin quality with lack of collagen and elastin, and recurrent jowling has been an indispensable and growing part of the author's practice. The synergy between the surgical and nonsurgical practice is examined, and this presentation will help the audience to understand how to maximize their usage of various newer indications for noninvasive devices. The rise in facelift patients is attributed to rapid weight loss with GLP-1 agonists and therefore younger patients

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Weight loss is the biggest stigma all around the globe and drug that gained attention was the GLP 1 agonist known as ozempic which has brought both positive and negative impact in Life. In aesthetic world ozempic fascies have referred to hollowness in cheeks extra skin laxity, atrophy of mid face and shift and deflating of fats hence different compartment acts differently.

Introduction: The advent of GLP-1 agonists like Ozempic has revolutionized weight management but has also introduced aesthetic challenges. As individuals lose weight, changes in facial structure, often referred to as "Ozempic fascies," can lead to a hollow appearance and skin laxity. These changes can negatively impact self-esteem and overall quality of life, prompting the need for effective aesthetic interventions. This study explores the use of specific dermal fillers to counteract these effects, aiming to restore facial volume and improve overall appearance while aligning with patient desires for natural

Materials / method: By considering the fact of adipose tissue different sizes with different septal network and different treatment modalities are selected to reuse such changes. In this split cohort study I utilized two types of dermal fillers. Polycaprolactone and Hyaluronic acid. Both fillers targeted superficial fat compartments replacement. To re-contour the deep nasolabial fold and re-shift the fats. I employed suspension sutures composing PCL-PLA micro, Nano and Sub-micro HA Capsules. Longevity is approximately 2 years assuming stable weight and moderate activities.

Results: Results show enhanced fascial rejuvenation with sustained effects on skin rejuvenation. This gives natural and subtle results aligning perfectly with the ultimate goal for our aesthetic patients.

Conclusion: This study demonstrates concurrent improvement in fat repositioning and filling.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。